Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C7H5O3.Mg.4H2O |
Molecular Weight | 370.5917 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.[Mg++].OC1=C(C=CC=C1)C([O-])=O.OC2=C(C=CC=C2)C([O-])=O
InChI
InChIKey=NBQBEWAYWAMLJJ-UHFFFAOYSA-L
InChI=1S/2C7H6O3.Mg.4H2O/c2*8-6-4-2-1-3-5(6)7(9)10;;;;;/h2*1-4,8H,(H,9,10);;4*1H2/q;;+2;;;;/p-2
DescriptionSources: http://www.drugbank.ca/drugs/DB00936https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdfCurator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html
Sources: http://www.drugbank.ca/drugs/DB00936https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdf
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html
Methyl salicylate (or methyl 2-hydroxybenzoate), also known as wintergreen oil, is a natural product and is present in white wine, tea, porcini mushroom Boletus edulis, Bourbon vanilla, clary sage, red sage and fruits including cherry, apple, raspberry, papaya and plum. Methyl salicylate is topically used in combination with methanol and under brand name SALONPAS to temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises. The precise mechanism of action of methyl salicylate is not known, but there is suggested, that it cause dilation of the capillaries thereby increasing blood flow to the area.
Originator
Sources: http://www.casinapioiv.va/content/dam/accademia/pdf/acta18/acta18-szczeklik.pdfhttps://books.google.ru/books?id=iUpwBAAAQBAJ&pg=PT83&lpg=PT83&dq=Methyl+salicylate+Auguste+Andr%C3%A9+Thomas+Cahours&source=bl&ots=nFDf2n2bpT&sig=wAKTDamdc7xWWgRxOrTeokeji8g&hl=ru&sa=X&ved=0ahUKEwj-q8769PzTAhVFfhoKHYEqDgkQ6AEIODAD#v=onepage&q=Methyl%20salicylate%20Auguste%20Andr%C3%A9%20Thomas%20Cahours&f=false
Curator's Comment: first isolated in 1843
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: http://www.drugbank.ca/drugs/DB00936 |
|||
Target ID: CHEMBL230 Sources: http://www.drugbank.ca/drugs/DB00936 |
|||
Target ID: CHEMBL2311236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26101955 |
1.48 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date2008 |
|||
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date2008 |
|||
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date2008 |
|||
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date2008 |
|||
Primary | Salicylic Acid Approved UseSalicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date2012 |
|||
Primary | Salicylic Acid Approved UseSalicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date2012 |
|||
Primary | Salicylic Acid Approved UseSalicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date2012 |
Doses
Dose | Population | Adverse events |
---|---|---|
30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: |
unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: |
Other AEs: Redness, Scales... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Redness | 30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: |
unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: |
|
Scales | 30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: |
unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/9207195/ |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
likely | ||||
major | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
[Identification and quantification of exogenous metabolites in biological liquids with new development in NMR spectroscopy in one and two dimensions]. | 1999 |
|
False-high blood salicylate levels in neonates with hyperbilirubinemia. | 2000 Dec |
|
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries. | 2001 |
|
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. | 2001 |
|
A novel jasmonic acid-inducible rice myb gene associates with fungal infection and host cell death. | 2001 Apr |
|
Nucleotide sequence analysis of 5'-flanking region of salicylate hydroxylase gene, and identification and purification of a LysR-type regulator, SalR. | 2001 Apr |
|
Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease. | 2001 Apr 17 |
|
Isolation and preliminary characterization of the medium-chain fatty acid:CoA ligase responsible for activation of short- and medium-chain fatty acids in colonic mucosa from swine. | 2001 Feb |
|
Molecular responses to aphid feeding in Arabidopsis in relation to plant defense pathways. | 2001 Feb |
|
The arabidopsis ISR1 locus controlling rhizobacteria-mediated induced systemic resistance is involved in ethylene signaling. | 2001 Feb |
|
3-Hydroxybenzoic acid as an internal standard for the high-pressure liquid chromatography quantitation of salicylic acid in plants. | 2001 Feb 1 |
|
Characterization of PBZ1, a probenazole-inducible gene, in suspension-cultured rice cells. | 2001 Jan |
|
Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. | 2001 Jan |
|
Reversed-phase high-performance liquid chromatography versus spectrophotometric assay for thimerosal in Cuban recombinant hepatitis B vaccine. | 2001 Jan 12 |
|
Salicylate and cocaine: interactive toxicity during chicken mid-embryogenesis. | 2001 Jan 15 |
|
Quantitative analysis of crystalline pharmaceuticals in powders and tablets by a pattern-fitting procedure using X-ray powder diffraction data. | 2001 Jan 16 |
|
Characterization of a rice (Oryza sativa L.) Bowman-Birk proteinase inhibitor: tightly light regulated induction in response to cut, jasmonic acid, ethylene and protein phosphatase 2A inhibitors. | 2001 Jan 24 |
|
Release of salicylic acid, diclofenac acid and diclofenac acid salts from isotropic and anisotropic nonionic surfactant systems across rat skin. | 2001 Jan 5 |
|
Increased sensitivity to sodium salicylate-induced apoptosis in drug-resistant leukemia L1210 cells. | 2001 Jan-Feb |
|
Combined cryotherapy/70% salicylic acid treatment for plantar verrucae. | 2001 Jan-Feb |
|
Interaction of the Arabidopsis receptor protein kinase Wak1 with a glycine-rich protein, AtGRP-3. | 2001 Jul 13 |
|
A novel pathway of aerobic benzoate catabolism in the bacteria Azoarcus evansii and Bacillus stearothermophilus. | 2001 Jul 6 |
|
Signaling mediated by the closely related mammalian Rho family GTPases TC10 and Cdc42 suggests distinct functional pathways. | 2001 Mar |
|
Quantitative analysis of analgoantipyretics in dosage form using planar chromatography. | 2001 Mar |
|
Potentiometric determination of acetylsalicylic acid by sequential injection analysis (SIA) using a tubular salicylate-selective electrode. | 2001 Mar |
|
In vivo evidence for accelerated generation of hydroxyl radicals in liver of Long-Evans Cinnamon (LEC) rats with acute hepatitis. | 2001 Mar 1 |
|
Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. | 2001 Mar 15 |
|
Binding of cosalane--a novel highly lipophilic anti-HIV agent--to albumin and glycoprotein. | 2001 May |
|
6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum. | 2001 May 8 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/salicylic-acid.html
The preferable method of use is to apply Salicylic Acid 6% thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for a least five minutes prior to application.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1811921
Salicylic acid inhibited hippuric acid formation in the homogenates obtained from the specimens of human liver with IC50 value 0.19 mM
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
3106 (Number of products:3)
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2106755
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
PRIMARY | |||
|
DB01397
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
PRIMARY | |||
|
5282387
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
PRIMARY | |||
|
C66050
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
PRIMARY | |||
|
253186
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
PRIMARY | |||
|
18917-95-8
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
PRIMARY | |||
|
100000076809
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
PRIMARY | |||
|
52364
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
ALTERNATIVE | |||
|
1374306
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
PRIMARY | |||
|
m7019
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB14444MIG
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
PRIMARY | |||
|
C496892
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
PRIMARY | |||
|
4510
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
PRIMARY | |||
|
41728CY7UX
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
PRIMARY | |||
|
41728CY7UX
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
PRIMARY | |||
|
DTXSID6046896
Created by
admin on Fri Dec 15 15:35:31 GMT 2023 , Edited by admin on Fri Dec 15 15:35:31 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD